Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
SomaLogic, Inc. specializes in proteomics, offering a unique platform for protein biomarker discovery and analysis. Its proprietary SomaScan technology enables high-throughput protein measurement, positioning it well in the rapidly growing field of personalized medicine and diagnostics.
SomaLogic generates revenue primarily through its SomaScan platform, which provides comprehensive protein analysis for research and clinical applications. The company leverages its proprietary technology to maintain pricing power, as it offers unique insights that are not easily replicated by competitors.
Adoption rates of SomaScan technology in clinical settings
Partnership announcements with pharmaceutical companies
Advancements in personalized medicine research
Regulatory approvals for new diagnostic tests
Technological disruption from new proteomics technologies
Regulatory changes affecting healthcare diagnostics
Emerging competitors with similar proteomics capabilities
Established diagnostic companies entering the proteomics space
Financial risk from negative cash flow impacting operational sustainability
Potential future capital needs for growth initiatives
moderate - As a healthcare technology firm, SomaLogic's demand can be influenced by overall healthcare spending, which is correlated with GDP growth.
Interest rates affect SomaLogic primarily through the cost of capital for funding R&D and operational expenses. Higher rates could constrain growth by increasing financing costs.
minimal - The company has no debt, which reduces its exposure to credit market fluctuations.
growth - Investors looking for exposure to innovative healthcare technologies and personalized medicine.
high - The stock has shown significant price fluctuations, particularly with a 1-year return of -40.5%.